Replies to post #113201 on Biotech Values

[DewDiligence]

Thanks for clearing up. I think it would do us MNTA shareholders some good to maybe put that in a PR.

As a matter of policy, most companies decline to comment on the regulatory status of competitors. MNTA could comment on today’s Teva PR, but that might lead to a slippery slope where MNTA’s not commenting on some future PR from a competitor would be interpreted by investors as tacit agreement with the contents.

Moreover, Lovenox is the subject of ongoing litigation between Teva and NVS/MNTA. When a matter is in litigation, saying less rather than more is usually the right thing to do.